Red Light Therapy for Depression & Mood: What the Research Says

The Short Answer

Red light therapy for depression is one of the more cautiously promising — and most easily oversold — applications of photobiomodulation (PBM). A small but growing body of research, mostly focused on transcranial photobiomodulation (near-infrared light applied to the forehead), suggests it may have measurable effects on mood and depressive symptoms in some people. The mechanisms are biologically plausible. The early human trials are encouraging. The catch is that the studies are small, methodologically varied, and far from the threshold needed to call red light therapy a treatment for major depressive disorder.

If you have moderate-to-severe depression, the appropriate first-line interventions are evidence-based therapies (such as cognitive behavioral therapy or interpersonal therapy), antidepressant medication where indicated, and lifestyle changes — under the care of a clinician. Red light therapy, at most, may turn out to be an adjunct. This article walks through what the research currently supports, where the gaps are, and how to think about it without overstating what the science says.

How Could Light Affect Mood at All?

The idea that shining infrared light on your forehead could influence mood sounds far-fetched until you understand the proposed biology. Photobiomodulation works at the cellular level: red and near-infrared photons are absorbed by cytochrome c oxidase, an enzyme in the mitochondrial electron transport chain. When stimulated, mitochondria may produce more ATP, modulate reactive oxygen species, and release nitric oxide. For a deeper dive on the cellular mechanism, see our photobiomodulation guide.

So why might that matter for depression? Several lines of evidence converge on a few overlapping ideas:

• Mitochondrial dysfunction is implicated in depression. A growing body of literature, including reviews in Molecular Psychiatry and Frontiers in Neuroscience, suggests that impaired mitochondrial bioenergetics may contribute to depressive symptoms, especially in treatment-resistant cases. Anything that improves neuronal mitochondrial function is at least theoretically interesting.
• Cerebral blood flow. Some imaging studies indicate transcranial PBM may transiently increase blood flow in the prefrontal cortex — a region consistently underactive in depression on functional imaging.
• Neuroinflammation. Chronic low-grade inflammation has been linked to depression in numerous studies. PBM has documented anti-inflammatory effects in peripheral tissue, and there is preliminary evidence it may reduce neuroinflammatory markers.
• BDNF and neuroplasticity. Brain-derived neurotrophic factor (BDNF) supports neuronal growth and plasticity, both of which are reduced in depression. Animal studies suggest PBM may upregulate BDNF expression in brain tissue.

These mechanisms are plausible but mostly unconfirmed in humans at the dosing parameters consumer devices deliver. Plausibility is a starting point, not proof.

What the Human Research Actually Shows

Here is where it pays to be specific, because the gap between “there is a study” and “this is well established” is enormous in this space.

The Schiffer 2009 Pilot Study

One of the earliest and most-cited studies was a small open-label trial published by Schiffer and colleagues in Behavioral and Brain Functions (2009). Ten patients with major depression and/or anxiety received a single transcranial near-infrared session (810nm) applied to the forehead. The investigators reported reductions in depression and anxiety scores at 2 and 4 weeks post-treatment. The sample was tiny, there was no placebo arm, and the duration of follow-up was short — but it sparked broader interest in the approach.

The Cassano Group at Mass General

A research group led by Paolo Cassano at Massachusetts General Hospital has produced several of the more rigorous tPBM-for-depression studies. A 2018 sham-controlled pilot RCT (Cassano et al., Photomedicine and Laser Surgery) tested transcranial 823nm light in adults with major depressive disorder. Active treatment showed numerically larger reductions in Hamilton Depression scores than sham, but the study was not large enough to be definitive.

A subsequent multi-site sham-controlled RCT (the ELATED-3 trial), published in 2022, did not find a statistically significant advantage for tPBM over sham at the primary endpoint. Both groups improved, and several secondary measures favored active treatment, but the headline result was negative. Honest summaries of the evidence have to acknowledge this.

Reviews and Meta-Analyses

Several systematic reviews (e.g., Caldieraro & Cassano in Behavioural Brain Research, 2019; Askalsky & Iosifescu in The Journal of Clinical Psychiatry, 2019) have concluded essentially the same thing: tPBM is biologically interesting, generally well tolerated, and shows preliminary signals worth following up — but the evidence base is too small and inconsistent for routine clinical use.

So the honest summary of the human research is: a handful of small trials, one notable mixed-or-negative larger trial, plausible mechanisms, and a clear consensus among researchers in the area that more, larger, better-controlled studies are needed before any strong claims can be made.

Bright Light Therapy vs Red Light Therapy — Don’t Confuse Them

This is one of the most common sources of confusion in popular coverage. Bright light therapy uses 10,000-lux white light directed into the eyes, typically for 20–30 minutes in the morning. It has decades of solid evidence for seasonal affective disorder (SAD) and reasonable evidence for non-seasonal depression as well. It works primarily through retinal pathways that influence circadian rhythm and the suprachiasmatic nucleus.

Red light therapy is something different: red (around 660nm) and near-infrared (around 810–850nm) LEDs applied to the skin, including the scalp or forehead in the case of transcranial PBM. The proposed mechanism is photobiomodulation in tissue rather than retinal signaling. See our full comparison of blue, white and red light wavelengths for context on why these effects differ.

If you are interested in light-based mood support and you have seasonal mood patterns, a 10,000-lux light box is the modality with the strongest evidence base by a wide margin. A red light panel is not a substitute for it.

Protocol Considerations (If You Want to Try It)

Given the early state of the evidence, we are not recommending red light therapy as a depression treatment. If, however, you already own a panel, are interested in experimenting alongside (not instead of) appropriate clinical care, and have discussed it with your doctor, here are the parameters most often cited in the research literature:

• Wavelength: Most transcranial studies have used 810nm or 823nm near-infrared, because longer wavelengths penetrate scalp and skull better than 660nm red. Some protocols combine 660nm + 810nm.
• Target area: The forehead, especially over the prefrontal cortex (roughly the upper third of the forehead). Some research has also targeted bilateral temple regions.
• Distance: 4–6 inches from the skin in published protocols, though this varies considerably by device irradiance. See our irradiance and dosing guide for what those parameters actually mean.
• Duration: Most studies used sessions in the range of 20–30 minutes, sometimes shorter for higher-irradiance devices.
• Frequency: Studies have ranged from twice weekly to daily. There is no settled “best” frequency.
• Eye safety: Always close your eyes, use the goggles supplied with your panel, and never look directly into a bright LED array. See our full safety guide.

For a larger, full-body option that can also be used at face height, the Hooga HGPro1500 covers more surface area but is harder to position close to the forehead.

What Has Stronger Evidence for Depression

If you are reading this article because you or someone you care about is struggling, the most useful thing we can do is point at interventions with solid evidence behind them. The list of approaches with stronger research support than red light therapy includes:

• Psychotherapy — especially cognitive behavioral therapy (CBT), behavioral activation, and interpersonal therapy. Multiple meta-analyses support effects comparable to medication for mild-to-moderate depression.
• Antidepressant medication when clinically indicated. Effects vary by individual, but the evidence base for established classes is extensive.
• Aerobic exercise. Multiple meta-analyses (including a large 2024 BMJ network meta-analysis) suggest moderate-to-large effects of structured exercise for depression, comparable to first-line treatments in some analyses.
• Sleep. Disrupted sleep is both a symptom and a driver of depression. Improving sleep often produces meaningful mood improvements. Our red light therapy for sleep guide covers the indirect path here.
• Bright light therapy for seasonal affective disorder (and, with smaller effect sizes, non-seasonal depression). 10,000-lux exposure in the morning is the standard.
• Social connection and behavioral activation — rebuilding routines, daily activity, and meaningful contact. Boring-sounding, well-supported, often the most actionable.

Red light therapy is not on that list yet. It might earn a spot eventually, but anyone marketing it as a primary treatment for depression today is overstating what the evidence supports.

The Honest Bottom Line

Transcranial photobiomodulation for depression is a research area worth watching. The mechanisms are plausible, the safety profile in studies has been favorable, and there are credible academic groups (Cassano at Mass General; the Schiffer group; others) actively investigating it. At the same time, the totality of human evidence is small, the largest sham-controlled trial to date did not show a clear advantage at its primary endpoint, and red light therapy is not an FDA-cleared treatment for any mental health condition.

If you already own a red light panel for skin, recovery, or sleep, occasional sessions targeted at the forehead are unlikely to do harm in healthy adults — provided you protect your eyes and use sensible session lengths. If you are looking for the most reliable ways to support your mental health, the boring fundamentals (sleep, exercise, therapy, medication where indicated, social connection, daylight exposure) have far stronger evidence than any consumer light panel.

We will update this article as larger, better-designed trials are published. The science is moving, but it is moving slowly, and the honest answer in 2026 is “interesting, plausible, not yet proven.”

If you are struggling. Depression is treatable, but it usually does not resolve through self-experiments alone. Please talk to a qualified mental health professional. In the U.S., the 988 Suicide & Crisis Lifeline is available 24/7 by calling or texting 988. Outside the U.S., a directory of international hotlines is available at findahelpline.com. You deserve real care, not a light panel.

Frequently Asked Questions

Can red light therapy actually help depression?

A small body of early-stage research, mostly using transcranial near-infrared photobiomodulation (light applied to the forehead), suggests possible mood improvements in some people with depression. The studies are small and inconsistent, and red light therapy is not FDA-approved for depression. It should not be used as a replacement for evidence-based mental health care.

What is transcranial photobiomodulation (tPBM)?

Transcranial photobiomodulation is the application of red or near-infrared light (most commonly around 810nm) to the scalp or forehead. The proposed goal is to stimulate underlying brain tissue, potentially enhancing neuronal mitochondrial function, modulating cerebral blood flow, and reducing neuroinflammation.

What wavelengths are used in depression research?

Most published depression and mood studies have used near-infrared light at 810nm or 823nm, because these longer wavelengths penetrate the scalp and skull more effectively than visible red light. Some protocols also include 660nm red wavelengths.

Is red light therapy a replacement for antidepressants or therapy?

No. Red light therapy is not an FDA-approved or evidence-validated replacement for antidepressant medication, psychotherapy, or other established treatments for depression. Anyone considering changing or stopping a mental health treatment should do so only under the guidance of a qualified clinician.

Is bright light therapy the same thing as red light therapy?

No. Bright light therapy uses high-lux white light (typically 10,000 lux) directed into the eyes and is well established for seasonal affective disorder. Red light therapy uses red and near-infrared LEDs applied to the skin or scalp and works through different proposed mechanisms.

Can red light therapy worsen depression or cause side effects?

Photobiomodulation is generally considered low-risk when used as directed. Side effects across studies have been mild and infrequent (e.g., temporary headache, eye strain). It has not been thoroughly studied in people with severe or treatment-resistant depression and should not substitute for proper mental health care.